OnKure Therapeutics (OKUR) Competitors $2.37 -0.09 (-3.47%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKUR vs. CYBN, CTOR, MOLN, CRDF, ACOG, ZURA, FBRX, MEIP, IVVD, and HURAShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Cybin (CYBN), Citius Oncology (CTOR), Molecular Partners (MOLN), Cardiff Oncology (CRDF), Alpha Cognition (ACOG), Zura Bio (ZURA), Forte Biosciences (FBRX), MEI Pharma (MEIP), Invivyd (IVVD), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors Cybin Citius Oncology Molecular Partners Cardiff Oncology Alpha Cognition Zura Bio Forte Biosciences MEI Pharma Invivyd TuHURA Biosciences Cybin (NYSE:CYBN) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Which has more volatility and risk, CYBN or OKUR? Cybin has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Which has preferable valuation and earnings, CYBN or OKUR? Cybin is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.60-1.29OnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.49 Do institutionals and insiders believe in CYBN or OKUR? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is CYBN or OKUR more profitable? Cybin's return on equity of -37.58% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% OnKure Therapeutics N/A -60.52%-55.43% Do analysts prefer CYBN or OKUR? Cybin presently has a consensus target price of $85.00, indicating a potential upside of 1,329.77%. OnKure Therapeutics has a consensus target price of $32.33, indicating a potential upside of 1,267.16%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than OnKure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25OnKure Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.14 Does the media refer more to CYBN or OKUR? In the previous week, Cybin had 5 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Cybin and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.89 beat Cybin's score of 0.14 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cybin Neutral OnKure Therapeutics Very Positive SummaryCybin and OnKure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.00M$3.11B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-0.4921.4175.1826.37Price / SalesN/A240.50457.0688.69Price / CashN/A44.4425.8129.91Price / Book0.309.6113.256.28Net Income-$52.67M-$53.20M$3.29B$270.67M7 Day Performance-10.08%0.18%0.72%2.79%1 Month Performance-6.52%4.02%4.58%6.01%1 Year PerformanceN/A9.21%73.44%26.05% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.7456 of 5 stars$2.37-3.5%$32.33+1,267.2%N/A$32.00MN/A-0.49N/APositive NewsGap DownCYBNCybin2.687 of 5 stars$6.27-6.8%$85.00+1,255.7%N/A$147.91MN/A-1.4350CTORCitius Oncology1.7986 of 5 stars$1.84-2.1%$3.00+63.0%+17.2%$147.34MN/A0.00N/AMOLNMolecular Partners2.2661 of 5 stars$3.59+0.3%$8.00+122.8%-29.6%$144.54M$5.65M-1.73180Gap UpCRDFCardiff Oncology3.0304 of 5 stars$2.23+2.8%$10.63+376.5%-24.4%$144.36M$680K-2.5620News CoveragePositive NewsACOGAlpha Cognition2.5461 of 5 stars$9.55+7.3%$20.00+109.4%N/A$143.83MN/A-5.97N/APositive NewsHigh Trading VolumeZURAZura Bio3.7579 of 5 stars$2.21+0.5%$14.00+533.5%-45.9%$143.04MN/A-3.163Short Interest ↓FBRXForte Biosciences3.3732 of 5 stars$11.13-1.2%$68.00+511.0%+45.1%$139.99MN/A-0.685Positive NewsMEIPMEI Pharma1.1388 of 5 stars$3.00-29.1%N/A+5.2%$138.91MN/A-0.63100Upcoming EarningsGap UpHigh Trading VolumeIVVDInvivyd3.4241 of 5 stars$1.16+1.8%$3.18+174.4%+24.3%$136.96M$25.38M-1.26100Short Interest ↑HURATuHURA Biosciences1.7538 of 5 stars$2.52-1.2%$12.67+402.6%N/A$127.62MN/A0.00N/A Related Companies and Tools Related Companies Cybin Alternatives Citius Oncology Alternatives Molecular Partners Alternatives Cardiff Oncology Alternatives Alpha Cognition Alternatives Zura Bio Alternatives Forte Biosciences Alternatives MEI Pharma Alternatives Invivyd Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
